---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-22-000043"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:43:24.525722+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q2 INGREZZA sales $350M (+32%), raises FY guidance to $1.35-1.40B; essential tremor Phase 2a fails

## Summary
- GAAP net loss $16.9M ($0.18 loss per diluted share) vs net income $42.3M in Q2 2021, largely due to $70M debt extinguishment loss.
- Non-GAAP net income $82.1M ($0.84 EPS) vs $70.1M ($0.72); INGREZZA net product sales $350M, up 32% YoY.
- Raised 2022 INGREZZA net product sales guidance to $1.35-1.40B from prior $1.30-1.35B; GAAP R&D guidance $415-450M.
- Phase 2a study of NBI-827104 in essential tremor did not meet endpoints; company discontinues development in that indication.
- Received $20M milestone from MTPC for DYSVAL launch in Japan; FDA cleared IND for NBI-1117568 (M4 agonist for schizophrenia) Phase 2.

## SEC filing metadata
- accession: 0000914475-22-000043
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447522000043/0000914475-22-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447522000043/nbix-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-22-000043
- JSON: https://secwatch.observer/filing/0000914475-22-000043.json
- Plain text: https://secwatch.observer/filing/0000914475-22-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.